Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25199418 | 1.00 | HTR2A (0.33) | HTR2AVCPKDM4EALDH1A1HPGD | |
| SCHEMBL25792125 | 0.86 | KDM4E (0.35) | HTR2AVCPKDM4EALDH1A1HPGD | |
| SCHEMBL25791379 | 0.84 | TAAR1 (0.44) | HTR2ATAAR1 | |
| SCHEMBL25195409 | 0.84 | PKM (0.37) | HTR2AVCPKDM4EALDH1A1HPGD | |
| SCHEMBL25791549 | 0.82 | DNMT1 (0.39) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL25791275 | 0.81 | — | — | |
| SCHEMBL25206802 | 0.80 | HTR2A (0.35) | HTR2ATAAR1 | |
| SCHEMBL25791467 | 0.80 | — | — | |
| SCHEMBL25209286 | 0.79 | CSF1R (0.38) | HTR2A | |
| SCHEMBL30429663 | 0.79 | CSF1R (0.38) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC. | 2026-03-19 | — | — | US | disclosed |
| EP-4423060-A2 | PSYCHOPLASTOGENIC N-SUBSTITUTED INDOLES | Terran Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, TPH1, HTR3D | HTR2A 13/4885VCP 4744/4885KDM4E 963/4885 |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | HTR2A 14/4885VCP 4229/4885KDM4E 1220/4885 |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TPH2, TPH1, AANAT | HTR2A 13/4885VCP 4330/4885KDM4E 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.